Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- Loop diuretics are the mainstay for congestion; standard heart failure with reduced ejection fraction (HFrEF) neurohormonal drugs are frequently poorly tolerated in restrictive physiology.
- Atrial fibrillation is common, and elevated thromboembolic and intracardiac-thrombus risk make anticoagulation a central decision.
- Rate control is challenging, and conduction disease may require pacing; device decisions are individualized.
- Digoxin and non-dihydropyridine calcium-channel blockers should be used with caution in ATTR-CM.
Heart Failure Management Works Within Restrictive Physiology
The infiltrated ventricle in ATTR-CM is stiff and operates with limited stroke volume reserve, which changes how heart failure drugs behave. Loop diuretics are the mainstay for managing congestion, titrated to relieve volume overload without provoking hypotension or worsening renal function. The neurohormonal drugs that anchor treatment of reduced ejection fraction heart failure—beta-blockers, renin-angiotensin system inhibitors or angiotensin receptor-neprilysin inhibitors, and mineralocorticoid receptor antagonists—are often poorly tolerated because patients may rely more heavily on heart rate and preload to maintain cardiac output and may have coexisting autonomic dysfunction. Management therefore tends to prioritize careful decongestion and tolerability, with these agents used cautiously and individually rather than as a fixed regimen.
Atrial Fibrillation and Thromboembolic Risk Drive Anticoagulation Decisions
Atrial fibrillation is common in ATTR-CM, and the amyloid-laden atrium carries an elevated risk of thromboembolism and intracardiac thrombus. For that reason, anticoagulation is frequently favored, and clinicians give particular weight to left atrial appendage thrombus risk, including obtaining imaging such as transesophageal echocardiography before cardioversion when appropriate. The combination of high thromboembolic risk and the practical challenges of rhythm control means anticoagulation is an important consideration—even when arrhythmia burden appears limited—while still individualizing for bleeding risk.
Rate Control, Conduction Disease, and Pacing
Rate and rhythm control are both harder in ATTR-CM than in typical atrial fibrillation. The drugs usually relied on for rate control are frequently limited by hypotension or bradycardia, and rhythm control strategies are constrained by the underlying substrate. Conduction system disease is a recognized feature of ATTR-CM, so atrioventricular (AV) block and the potential need for pacing should be monitored. The role of implantable defibrillators is less settled and is decided case by case, weighing arrhythmic risk against overall prognosis and goals of care.
Drugs to Use with Caution
Several commonly used cardiac drugs warrant extra caution in ATTR-CM because of the disease's physiology and the behavior of amyloid tissue. The most frequently cited cautions include:
- Digoxin, which has traditionally been used cautiously because of reports that it binds amyloid fibrils and may carry a higher risk of toxicity
- Non-dihydropyridine calcium-channel blockers such as verapamil and diltiazem, which can be poorly tolerated and have been associated with adverse effects in cardiac amyloidosis
- Aggressive use of standard neurohormonal heart failure drugs, which may precipitate hypotension given the limited output reserve
These are cautions—not blanket prohibitions—and decisions should be individualized in coordination with a clinician experienced in cardiac amyloidosis.
Practical Co-Management Checklist
In a patient with ATTR-CM and arrhythmia or congestion, reassess:
- Is congestion being managed primarily with loop diuretics, titrated to volume and renal function?
- Are neurohormonal heart failure drugs being tolerated, or are they causing hypotension?
- Has anticoagulation been considered given the elevated thromboembolic risk in atrial fibrillation?
- Is intracardiac thrombus risk addressed before cardioversion, including appropriate imaging when indicated?
- Is conduction disease being monitored, with pacing anticipated if needed?
- Are digoxin and non-dihydropyridine calcium-channel blockers being used cautiously and with appropriate monitoring?
Clinical Decision Point
The recurring decision in ATTR-CM co-management is how hard to push therapies that are standard elsewhere but poorly tolerated here. Congestion is generally managed with careful loop diuretic titration; the harder calls are whether neurohormonal drugs can be tolerated at all, how decisively to anticoagulate in atrial fibrillation, and which rate or rhythm control and device strategies fit the patient's substrate and goals. When standard therapies carry more risk than benefit, careful individualization and coordination with a clinician experienced in cardiac amyloidosis are recommended.
Frequently Asked Questions
How is heart failure managed in ATTR-CM?
Management centers on careful decongestion with loop diuretics, titrated to volume status and renal function. Standard neurohormonal heart failure drugs are often poorly tolerated because of the stiff, low-output ventricle and autonomic dysfunction, so they are used cautiously and individually rather than as a fixed regimen.
Why is anticoagulation emphasized in ATTR-CM with atrial fibrillation?
Anticoagulation is often emphasized because the amyloid-affected atrium carries elevated thromboembolic and intracardiac thrombus risk. Anticoagulation is frequently favored, and left atrial appendage thrombus risk is taken seriously, including imaging before cardioversion when appropriate, while still individualizing for bleeding risk.
Which drugs should be used with caution?
Digoxin has traditionally been used cautiously because of reported binding to amyloid fibrils and toxicity risk, and non-dihydropyridine calcium-channel blockers such as verapamil and diltiazem can be poorly tolerated. Aggressive neurohormonal therapy may also precipitate hypotension. These are cautions to individualize, not absolute prohibitions.
Do patients with ATTR-CM need a pacemaker or defibrillator?
Conduction disease is part of ATTR-CM, so AV block and the need for pacing should be anticipated and monitored. The role of implantable defibrillators is less settled and is decided case by case, weighing arrhythmic risk against overall prognosis and goals of care.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Manage the Disease
Next Clinical Decision
See the Evidence
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Expert Consensus on the Monitoring of Transthyretin Amyloid Cardiomyopathy. European Journal of Heart Failure
- Stroke Risk and Atrial Mechanical Dysfunction in Cardiac Amyloidosis. European Journal of Heart Failure
- Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy: A Marker of Disease Severity but Not an Independent Predictor of Mortality. Cureus
This content is intended for healthcare professionals for educational purposes and isn't a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.